Organon & Co. Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents
Organon & Co. (OGN) reported Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents of -$34.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Cash Flow › Change in Cash
us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-07-31
- Organon & Co. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2026-03-31 was -$31.00M, a 170.45% decline year-over-year.
- Organon & Co. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2025-03-31 was $44.00M.
- Organon & Co. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2024-03-31 was -$24.00M, a 226.32% decline year-over-year.
- Organon & Co. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2023-03-31 was $19.00M.
- Organon & Co. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2025 was $150.00M.
- Organon & Co. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2024 was -$76.00M, a 547.06% decline from fiscal 2023.
- Organon & Co. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2023 was $17.00M.
- Organon & Co. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2022 was -$36.00M, a 256.52% decline from fiscal 2021.
| Period end | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 9 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$34.00M 10-Q · filed 2026-07-31 | |||
| 2026-03-31 | -$31.00M 10-Q · filed 2026-05-04 | |||
| 2025-12-31 | $150.00M 10-K · filed 2026-02-24 | |||
| 2025-09-30 | $137.00M 10-Q · filed 2025-11-10 | |||
| 2025-06-30 | $137.00M 10-Q · filed 2026-07-31 | |||
| 2025-03-31 | $44.00M 10-Q · filed 2026-05-04 | |||
| 2024-12-31 | -$76.00M 10-K · filed 2026-02-24 | |||
| 2024-09-30 | $24.00M 10-Q · filed 2025-11-10 | |||
| 2024-06-30 | -$47.00M 10-Q · filed 2025-08-06 | |||
| 2024-03-31 | -$24.00M 10-Q · filed 2025-05-02 | |||
| 2023-12-31 | $17.00M 10-K · filed 2026-02-24 | |||
| 2023-09-30 | -$23.00M 10-Q · filed 2024-11-01 | |||
| 2023-06-30 | $17.00M 10-Q · filed 2024-08-07 | |||
| 2023-03-31 | $19.00M 10-Q · filed 2024-05-03 | |||
| 2022-12-31 | -$36.00M 10-K/A · filed 2025-11-10 | |||
| 2022-09-30 | -$119.00M 10-Q · filed 2023-11-03 | |||
| 2022-06-30 | -$46.00M 10-Q · filed 2023-08-09 | |||
| 2022-03-31 | -$12.00M 10-Q · filed 2023-05-05 | |||
| 2021-12-31 | $23.00M 10-K · filed 2024-02-26 | |||
| 2021-09-30 | $21.00M 10-Q · filed 2022-11-04 | |||
| 2021-06-30 | $32.00M 10-Q · filed 2022-08-05 | |||
| 2021-03-31 | -$13.00M 10-Q · filed 2022-05-06 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-02-27 | |||
| 2020-09-30 | $0.00 10-Q · filed 2021-11-12 | |||
| 2020-06-30 | $0.00 10-Q · filed 2021-08-16 | |||
| 2020-03-31 | $0.00 10-Q · filed 2021-06-21 | |||
| 2019-12-31 | $0.00 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |